secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039348
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics Q2 2023 net loss $3.1M; highlights positive AD and ALS clinical data
--------------------------------------------------------------------------------

- Net loss of $3.1M ($0.31 per share) for Q2 2023 vs $3.4M loss in Q2 2022.
- Cash and equivalents $13.1M as of June 30, 2023, up from $5.9M at Dec 31, 2022.
- Positive PoC data for ld IL-2 in Alzheimer's: statistically significant MMSE improvement and reduced neuroinflammation.
- ALS study of COYA 302 halted disease progression at 24 weeks; pre-IND meeting with FDA planned for H2 2023.
- Appointed Dr. Fred Grossman as President/CMO and Arun Swaminathan as CBO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000095017023039348/0000950170-23-039348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000095017023039348/coya-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer